Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Brenning

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|October 1, 1985
Evaluation of serum deoxythymidine kinase as a marker in multiple myelomaB Simonsson, C F Källander, G Brenning, et al.
Lakartidningen|September 7, 1994
[The MEDGER document. A new document for cooperation between internal medicine and geriatrics]T Kjellström, B G Hansson, G Brenning, et al.
Blood|March 15, 1993
Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central SwedenA Osterborg, M Björkholm, M Björeman, et al.
European Journal of Haematology|July 1, 1989
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCSA Osterborg, A Ahre, M Björkholm, et al.
British Journal of Haematology|October 1, 1991
Treatment of multiple myeloma with interferon alpha: the Scandinavian experienceH Mellstedt, A Osterborg, M Björkholm, et al.
European Journal of Haematology|August 1, 1988
High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma--a pilot study from the Myeloma Group of Central Sweden (MGCS)A Ahre, M Björkholm, A Osterborg, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1990
Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central SwedenA Osterborg, A Ahre, M Björkholm, et al.
Cancer Treatment Reports|November 1, 1984
Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central SwedenA Ahre, M Björkholm, H Mellstedt, et al.
European Journal of Haematology. Supplementum|January 1, 1989
Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCSH Mellstedt, A Osterborg, M Björkholm, et al.
European Journal of Haematology|July 1, 1993
Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myelomaM Ohrling, M Björkholm, A Osterborg, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|October 1, 1985
Evaluation of serum deoxythymidine kinase as a marker in multiple myelomaB Simonsson, C F Källander, G Brenning, et al.
Lakartidningen|September 7, 1994
[The MEDGER document. A new document for cooperation between internal medicine and geriatrics]T Kjellström, B G Hansson, G Brenning, et al.
Blood|March 15, 1993
Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central SwedenA Osterborg, M Björkholm, M Björeman, et al.
European Journal of Haematology|July 1, 1989
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCSA Osterborg, A Ahre, M Björkholm, et al.
British Journal of Haematology|October 1, 1991
Treatment of multiple myeloma with interferon alpha: the Scandinavian experienceH Mellstedt, A Osterborg, M Björkholm, et al.
European Journal of Haematology|August 1, 1988
High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma--a pilot study from the Myeloma Group of Central Sweden (MGCS)A Ahre, M Björkholm, A Osterborg, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1990
Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central SwedenA Osterborg, A Ahre, M Björkholm, et al.
Cancer Treatment Reports|November 1, 1984
Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central SwedenA Ahre, M Björkholm, H Mellstedt, et al.
European Journal of Haematology. Supplementum|January 1, 1989
Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCSH Mellstedt, A Osterborg, M Björkholm, et al.
European Journal of Haematology|July 1, 1993
Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myelomaM Ohrling, M Björkholm, A Osterborg, et al.
Pageof 3